Novel insights into the pathobiology of humoral alloimmune memory in kidney transplantation.
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
10
12
2019
medline:
24
10
2020
entrez:
10
12
2019
Statut:
ppublish
Résumé
Humoral alloimmunity against human leukocyte antigen (HLA) antigens is the main barrier for successful transplantation. Recent researches have shown that this complex effector immune mechanism is driven by a number of B-cell subsets, which can orchestrate in a perfect and synergistic multistep manner the rejection of the organ transplant. Herein, our purpose is to review the immunobiology of humoral response and discuss novel therapeutic strategies derived from this evidence. Among the distinct cellular components of the humoral alloimmune system, memory B cells (mBC) have been shown to play a key role initiating and maintaining the antidonor humoral alloimmune response, thus its assessment apart from monitoring donor (HLA)-specific antibodies (DSA) in the sera may improve the understanding of the alloimmune status of transplant patients at different time points. Furthermore, targeting alloreactive mBC as well as other B and T-cell counterparts have highlighted for the first time, that novel therapeutic strategies with a more mechanistic rationale are highly warranted for achieving an effective anti-HLA humoral alloimmune control, also in human kidney transplantation. The complex mechanisms of humoral allorecognitition in transplantation seem to be progressively better understood with the implementation of novel immune technologies. This new insight should serve for the development of novel immunosuppressive strategies to achieve an optimal humoral alloimmune regulation.
Identifiants
pubmed: 31815788
doi: 10.1097/MOT.0000000000000717
pii: 00075200-202002000-00004
doi:
Substances chimiques
HLA Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-21Références
Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378:1428–1437.
Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90:68–74.
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735–739.
Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23:2061–2071.
Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and nondonor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16:2804–2812.
Lachmann N, Terasaki PI, Budde K, et al. Antihuman leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87:1505–1513.
Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398–1406.
Crotty S, Ahmed R. Immunological memory in humans. Semin Immunol 2004; 16:197–203.
Luque S, Lúcia M, Bestard O. Refinement of humoral immune monitoring in kidney transplantation: the role of ‘hidden’ alloreactive memory B cells. Transpl Int 2017; 30:955–968.
Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272:54–60.
Mills DM, Cambier JC. B lymphocyte activation during cognate interactions with CD4+ T lymphocytes: molecular dynamics and immunologic consequences. Semin Immunol 2003; 15:325–329.
Baxter AG, Hodgkin PD. Activation rules: the two-signal theories of immune activation. Nat Rev Immunol 2002; 2:439.
Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005; 5:230.
Basso K, Klein U, Niu H, et al. Tracking CD40 signaling during germinal center development. Blood 2004; 104:4088–4096.
Tokoyoda K, Hauser AE, Nakayama T, et al. Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 2010; 10:193.
Moran I, Nguyen A, Khoo WH, et al. Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. Nat Commun 2018; 9:3372.
Iwakoshi NN, Ford ML. Identifying diversity within memory B cell populations. Literature watch: implications for transplantation. Am J Transplant 2015; 15:577.
Zuccarino-Catania GV, Sadanand S, Weisel FJ, et al. CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nat Immunol 2014; 15:631.
Obukhanych TV, Nussenzweig MC. T-independent type II immune responses generate memory B cells. J Exp Med 2006; 203:305–310.
Palm AK, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol 2019; 10:1787.
Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10:252–258.
Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199–2202.
Turner JS, Marthi M, Benet ZL, Grigorova I. Transiently antigen-primed B cells return to naive-like state in absence of T-cell help. Nat Commun 2017; 8:15072.
Sutton PM, Harmer AH, Bayne AM, Welsh KI. The flow cytometric detection of alloantibodies in screening for renal transplantation. Transpl Int 1995; 8:360–365.
Gibney EM, Cagle LR, Freed B, et al. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006; 21:2625–2629.
Chong AS. Alone again naturally: B cells encountering antigen without T cells. Transplantation 2017; 101:1956–1958.
Billen EV, Christiaans MH, Lee J, van den Berg-Loonen EM. Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay. Transplantation 2009; 87:563–569.
Magee JC, Barr ML, Basadonna GP, et al. Repeat organ transplantation in the United States. Am J Transplant 2007; 7:1424–1433.
Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12:1168–1179.
Tambur AR, Campbell P, Claas FH, et al. Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report. Am J Transplant 2018; 18:1604–1614.
Streitz M, Miloud T, Kapinsky M, et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res 2013; 2:17.
Neumann B, Klippert A, Raue K, et al. Characterization of B and plasma cells in blood, bone marrow, and secondary lymphoid organs of rhesus macaques by multicolor flow cytometry. J Leuk Biol 2015; 97:19–30.
Mulder A, Eijsink C, Kardol MJ, et al. Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers. J Immunol 2003; 171:6599–6603.
Kwun J, Oh BC, Gibby AC, et al. Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. Am J Transplant 2012; 12:2641–2651.
Pape KA, Taylor JJ, Maul RW, et al. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011; 331:1203–1207.
Chen J, Yin H, Xu J, et al. Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am J Transplant 2013; 13:2280–2292.
Li Y, Ma L, Shen J, Chong AS. Peripheral deletion of mature alloreactive B cells induced by costimulation blockade. Proc Natl Acad Sci 2007; 104:12093–12098.
Zachary AA, Kopchaliiska D, Montgomery RA, et al. HLA-specific B cells: II: application to transplantation. Transplantation 2007; 83:989–994.
Mulder A, Kardol MJ, Arn JS, et al. Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. Mol Immunol 2010; 47:809–815.
Correa I, Ilieva KM, Crescioli S, et al. Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells. Front Immunol 2018; 9:493.
Degauque N, Ngono AE, Akl A, et al. Characterization of antigen-specific B cells using nominal antigen-coated flow-beads. PLoS One 2013; 8:e84273.
Buisman AM, De Rond CG, Öztürk K, et al. Long-term presence of memory B-cells specific for different vaccine components. Vaccine 2009; 28:179–186.
Pinna D, Corti D, Jarrossay D, et al. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol 2009; 39:1260–1270.
Jahnmatz M, Kesa G, Netterlid E, et al. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. J Immunol Methods 2013; 391:50–59.
Karahan GE, de Vaal Y, Roelen DL, et al. nGE, quantification of HLA class II-specific memory B cells in HLA-sensitized individuals. Hum Immunol Am Soc Histocompatibi Immunogenet 2015; 76:129–136.
Heidt S, Roelen D, de Vaal YJ, et al. A novel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals. Am J Transplant 2012; 12:1469.
Karahan GE. A memory B cell crossmatch assay for quantification of donor-specific memory B cells in the peripheral blood of HLA-immunized individuals. Am J Transplant 2017; 17:2617–2626.
Lynch RJ, Silba IA, Chen BJ, et al. Cryptic B cell response to renal transplantation. Am J Transplant 2013; 13:1713–1723.
Luque S, Lúcia M, Crespo E, et al. A multicolour HLA-specific B-cell FluoroSpot assay to functionally track circulating HLA-specific memory B cells. J Immunol Methods 2018; 462:23–33.
Lúcia M, Luque S, Crespo E, et al. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. Kidney Int 2015; 88:874–887.
Luque S, Lúcia M, Melilli E, et al. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation. Am J Transplant 2019; 19:368–380.
Bernasconi NL. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199–2202.
Kim I. Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. Transplant Immunol 2016; 38:84–92.
Yang J. Tracing donor-MHC class II reactive B cells in mouse cardiac transplantation. Transplantation 2016; 100:1683–1691.
Han M. Peripheral blood B cells producing donor-specific HLA antibodies in vitro. Hum Immunol 2009; 70:29.
Snanoudj R. Restricted specificity of peripheral alloreactive memory B cells in HLA sensitized patients awaiting a kidney transplant. Kidney Int 2015; 87:1230.
Han M, Rogers JA, Lavingia B, et al. Peripheral blood B cells producing donor-specific HLA antibodies in vitro. Hum Immunol 2009; 70:29–34.
Snanoudj R, Claas FH, Heidt S, et al. Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney Int 2015; 87:1230–1240.
Karahan GE, Krop J, Wehmeier C, et al. An easy and sensitive method to profile the antibody specificities of HLA-specific memory B cells. Transplantation 2019; 103:716–723.
Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111.
Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24:572.
Czerkinsky CC, Nilsson LA, Nygren H, et al. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 65:109–121.
Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med 2016; 374:940–950.
Woodle ES, Shields AR, Ejaz NS, et al. Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant 2015; 15:101–118.
Moreso F, Crespo M, Ruiz JC, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant 2018; 18:927–935.
Eskandary F, Regele H, Baumann L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 2018; 29:591–605.
Süsal C, Opelz G. Desensitization and survival in kidney transplant recipients. Nat Rev Nephrol 2017; 13:196.
Manook M, Koeser L, Ahmed Z, et al. Postlisting survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. Lancet 2017; 389:727–734.
Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014; 14:1573–1580.
Kwun J, Burghuber C, Manook M, et al. Humoral compensation after bortezomib treatment of allosensitized recipients. J Am Soc Nephrol 2017; 28:1991–1996.
Kwun J, Matignon M, Manook M, et al. Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use. J Am Soc Nephrol 2019; 30:1206–1219.
Chong AS. New insights into the development of B cell responses: implications for solid organ transplantation. Hum Immunol 2019; 80:378–384.
Bray RA, Gebel HM, Townsend R, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant 2018; 18:1783–1789.
Bray RA, Gebel HM, Townsend R, et al. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant 2018; 18:1774–1782.
Leibler C, Thiolat A, Hénique C, et al. Control of humoral response in renal transplantation by belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk. J Am Soc Nephrol 2018; 29:1049–1062.
Kwun J, Burghuber C, Manook M, et al. Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. Blood Adv 2017; 1:2115–2119.
Burghuber CK, Manook M, Ezekian B, et al. Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. Am J Transplant 2019; 19:724–736.
Kim I, Wu G, Chai NN, et al. Antisinterleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation 2014; 98:1262–1270.
Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 2017; 17:2381–2389.